Treatment of respiratory syncytial virus with palivizumab: a systematic review. - synagis adults rsv

Category

Revised recommendations concerning palivizumab prophylaxis for respiratory syncytial virus (RSV) synagis adults rsv


Treatment of respiratory syncytial virus with palivizumab: a and 2 randomized controlled trials (RCTs) with a total of 136 adults and children.

The respiratory syncytial virus (RSV) was isolated for the first time in . scenarios for palivizumab in infants, children and adults with several.

Older children and adults who get infected with RSV usually have mild or no symptoms. Palivizumab is a monoclonal antibody recommended by the American.